{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:48:27Z","timestamp":1761821307226},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T00:00:00Z","timestamp":1371772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00702-013-1055-4","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T05:55:43Z","timestamp":1371707743000},"page":"55-60","source":"Crossref","is-referenced-by-count":5,"title":["Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards"],"prefix":"10.1007","volume":"120","author":[{"given":"Clemens","family":"Warnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrneurol.2010.76","volume":"6","author":"O Aktas","year":"2010","unstructured":"Aktas O, K\u00fcry P, Kieseier B, Hartung HP (2010) Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6:373\u2013382","journal-title":"Nat Rev Neurol"},{"issue":"20","key":"1055_CR2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870\u20131880. doi: 10.1056\/NEJMoa1107829","journal-title":"N Engl J Med"},{"issue":"17","key":"1055_CR3","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"CAMMS Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786\u20131801. doi: 10.1056\/NEJMoa0802670","journal-title":"N Engl J Med"},{"issue":"9856","key":"1055_CR4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. doi: 10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"9856","key":"1055_CR5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS I investigators (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. doi: 10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"issue":"3","key":"1055_CR6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21813","volume":"66","author":"LM DeAngelis","year":"2009","unstructured":"DeAngelis LM (2009) Natalizumab: a double-edged sword? Ann Neurol 66(3):262\u2013263. doi: 10.1002\/ana.21813","journal-title":"Ann Neurol"},{"issue":"12","key":"1055_CR7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","volume":"33","author":"B Engelhardt","year":"2012","unstructured":"Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 33(12):579\u2013589. doi: 10.1016\/j.it.2012.07.004","journal-title":"Trends Immunol"},{"issue":"1","key":"1055_CR8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1474-4422(08)70281-3","volume":"8","author":"HP Hartung","year":"2009","unstructured":"Hartung HP (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8(1):28\u201331. doi: 10.1016\/S1474-4422(08)70281-3","journal-title":"Lancet Neurol"},{"issue":"7","key":"1055_CR9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00415-006-0486-3","volume":"254","author":"HP Hartung","year":"2007","unstructured":"Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS (2007) Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol 254(7):827\u2013837. doi: 10.1007\/s00415-006-0486-3","journal-title":"J Neurol"},{"issue":"3","key":"1055_CR10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/ern.11.15","volume":"11","author":"HP Hartung","year":"2011","unstructured":"Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T (2011) Principles of a new treatment algorithm in multiple sclerosis. Expt Rev Neurother 11(3):351\u2013362. doi: 10.1586\/ern.11.15","journal-title":"Expt Rev Neurother"},{"issue":"7","key":"1055_CR11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, Group HT (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. doi: 10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"issue":"3","key":"1055_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O\u2019Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8(3):254\u2013260. doi: 10.1016\/S1474-4422(09)70021-3","journal-title":"Lancet Neurol"},{"key":"1055_CR13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.wco.0000227037.70329.b0","volume":"19","author":"B Hemmer","year":"2006","unstructured":"Hemmer B, Frohman E, Hartung H-P, St\u00fcve O (2006) Central nervous system infections: a potential complication of systemic immunotherapy. Curr Opin Neurol 19:271\u2013276","journal-title":"Curr Opin Neurol"},{"issue":"7359","key":"1055_CR14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D\u2019Alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D\u2019Hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppa V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Ruckert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sorensen PS, Sondergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvanen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214\u2013219. doi: 10.1038\/nature10251","journal-title":"Nature"},{"issue":"3","key":"1055_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285\u2013294. doi: 10.1002\/ana.410390304","journal-title":"Ann Neurol"},{"issue":"7","key":"1055_CR16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268\u20131276","journal-title":"Neurology"},{"issue":"Pt 8","key":"1055_CR17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/brain\/awq176","volume":"133","author":"JL Jones","year":"2010","unstructured":"Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ (2010) Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133(Pt 8):2232\u20132247. doi: 10.1093\/brain\/awq176","journal-title":"Brain"},{"issue":"9805","key":"1055_CR18","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779\u20131787. doi: 10.1016\/S0140-6736(11)61649-8","journal-title":"Lancet"},{"issue":"3","key":"1055_CR19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WCO.0b013e32834696dd","volume":"24","author":"BC Kieseier","year":"2011","unstructured":"Kieseier BC, Wiendl H, Hartung HP, Leussink VI, Stuve O (2011) Risks and benefits of multiple sclerosis therapies: need for continual assessment? Curr Opin Neurol 24(3):238\u2013243. doi: 10.1097\/WCO.0b013e32834696dd","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"1055_CR20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","volume":"71","author":"BK Kleinschmidt-DeMasters","year":"2012","unstructured":"Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T (2012) Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71(7):604\u2013617. doi: 10.1097\/NEN.0b013e31825caf2c","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"1055_CR21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375\u2013381. doi: 10.1056\/NEJMoa051847","journal-title":"N Engl J Med"},{"issue":"1","key":"1055_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1756285608093978","volume":"1","author":"RA Linker","year":"2008","unstructured":"Linker RA, Kieseier BC (2008) Innovative monoclonal antibody therapies in multiple sclerosis. Therap Adv Neurol Disorders 1(1):43\u201352. doi: 10.1177\/1756285608093945","journal-title":"Therap Adv Neurol Disorders"},{"issue":"9","key":"1055_CR23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910. doi: 10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"key":"1055_CR24","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352(9139):1498\u20131504"},{"key":"1055_CR25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WCO.0b013e328346d47d","volume":"24","author":"DS Riminton","year":"2011","unstructured":"Riminton DS, Hartung HP, Reddel SW (2011) Managing the risks of immunosuppression. Curr Opin Neurol 24:217\u2013223","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"1055_CR26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911\u2013923. doi: 10.1056\/NEJMoa044396","journal-title":"N Engl J Med"},{"issue":"11","key":"1055_CR27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","volume":"21","author":"N Schmedt","year":"2012","unstructured":"Schmedt N, Andersohn F, Garbe E (2012) Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Safety 21(11):1216\u20131220. doi: 10.1002\/pds.3320","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"Suppl 10","key":"1055_CR28","first-page":"S358","volume":"17","author":"E Sundqvist","year":"2011","unstructured":"Sundqvist E, Warnke C, Khademi M (2011) Genetic influence on anti-JC-virus antibody seropositivity in MS patients and controls. Multi Scler 17(Suppl 10):S358","journal-title":"Multi Scler"},{"issue":"7","key":"1055_CR29","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","volume":"45","author":"The IFNB Multiple Sclerosis Study Group","year":"1995","unstructured":"The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS\/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7):1277\u20131285","journal-title":"Neurology"},{"issue":"4","key":"1055_CR30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353(4):362\u2013368. doi: 10.1056\/NEJMoa051586","journal-title":"N Engl J Med"},{"key":"1055_CR31","first-page":"333","volume":"5","author":"C Warnke","year":"2009","unstructured":"Warnke C, Meyer zu Horste G, Hartung HP, Stuve O, Kieseier BC (2009) Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treatm 5:333\u2013340","journal-title":"Neuropsychiatr Dis Treatm"},{"issue":"8","key":"1055_CR32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","volume":"67","author":"C Warnke","year":"2010","unstructured":"Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stuve O (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67(8):923\u2013930. doi: 10.1001\/archneurol.2010.161","journal-title":"Arch Neurol"},{"issue":"4","key":"1055_CR33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00115-010-3091-8","volume":"82","author":"C Warnke","year":"2011","unstructured":"Warnke C, Adams O, Gold R, Hartung HP, Hohlfeld R, Wiendl H, Kieseier BC (2011a) Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification? Der Nervenarzt 82(4):475\u2013480. doi: 10.1007\/s00115-010-3091-8","journal-title":"Der Nervenarzt"},{"issue":"10","key":"1055_CR34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00115-011-3319-2","volume":"82","author":"C Warnke","year":"2011","unstructured":"Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC (2011b) Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology. Der Nervenarzt 82(10):1314\u20131319. doi: 10.1007\/s00115-011-3319-2","journal-title":"Der Nervenarzt"},{"key":"1055_CR35","first-page":"519","volume":"7","author":"C Warnke","year":"2011","unstructured":"Warnke C, Stuve O, Hartung HP, Fogdell-Hahn A, Kieseier BC (2011c) Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treatm 7:519\u2013527. doi: 10.2147\/NDT.S10481","journal-title":"Neuropsychiatr Dis Treatm"},{"issue":"1","key":"1055_CR36","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.4081\/dts.2012.e11","volume":"2","author":"C Warnke","year":"2012","unstructured":"Warnke C, Hermanrud C, Lundkvist M, Fogdell-Hahn A (2012) Anti-drug antibodies. Drugs Ther Stud 2(1):e11","journal-title":"Drugs Ther Stud"},{"key":"1055_CR37","doi-asserted-by":"crossref","unstructured":"Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O (2013a) An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multi Scler [Epub ahead of print]","DOI":"10.1177\/1352458513475489"},{"key":"1055_CR38","doi-asserted-by":"crossref","unstructured":"Warnke C, Ramanujam R, Plavina T, Bergstr\u00f6m T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holm\u00e9n C, Olsson T, Hillert J, Fogdell-Hahn A (2013b) Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry [Epub ahead of print]","DOI":"10.1136\/jnnp-2012-304332"},{"issue":"3","key":"1055_CR39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrneurol.2013.2","volume":"9","author":"H Wiendl","year":"2013","unstructured":"Wiendl H, Kieseier B (2013) Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol 9(3):125\u2013126. doi: 10.1038\/nrneurol.2013.2","journal-title":"Nat Rev Neurol"},{"issue":"6364","key":"1055_CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63\u201366. doi: 10.1038\/356063a0","journal-title":"Nature"},{"issue":"9","key":"1055_CR41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354(9):924\u2013933. doi: 10.1056\/NEJMoa054693","journal-title":"N Engl J Med"},{"issue":"5","key":"1055_CR42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72(5):779\u2013787. doi: 10.1002\/ana.23676","journal-title":"Ann Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1055-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1055-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T22:48:54Z","timestamp":1563230934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,21]]},"references-count":42,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1055-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,21]]}}}